Author(s):
Harshal D. Patil, Chandrabhan B Patil, Vikas V. Patil, Pankaj S. Patil
Email(s):
chandrabhanpatil123@gmail.com , Harshalpatil27896@gmail.com
DOI:
10.52711/2231-5659.2023.00009 
Address:
Harshal D. Patil*, Chandrabhan B Patil*, Vikas V. Patil, Pankaj S. Patil
Department of Pharmaceutical Quality Assurance, Kisan Vidya Prasarak Sanstha’s Institute of Pharmaceutical Education, Boradi 425428.
*Corresponding Author
Published In:
Volume - 13,
Issue - 1,
Year - 2023
ABSTRACT:
Quality by Design (QbD) has as a new concept for the development of high-quality pharmaceutical products. It is an essential component of the modern approach to pharmaceutical quality. QbD is the best way to build quality into all pharmaceutical products, but it poses a significant challenge to the pharmaceutical industry, whose processes are time-bound, despite inherent process and material variability. Throughout the design and development of a product, it is critical to define the desired product performance profile [Target Product Profile (TPP), Target Product Quality Profile (TPQP)] and identify critical quality attributed to the product (CQA). Applications of QbD to pharmaceutical processes (formulation development) and analytical development are briefly discussed. A standardized pharmaceutical quality system that is applicable throughout the product's lifecycle and emphasizes an integrated approach to risk management and science should be developed, resulting in better quality medicines for patients.ICH documents such as ICH Q8, i.e. Pharmaceutical development; ICH Q9, i.e. Quality Risk Management; ICH Q10, i.e. Pharmaceutical Quality Systems, and FDA's Process Analytical Technology (PAT) were referred to in order to ensure drug product quality. QbD allows formulation and manufacturing variables to be properly understood and controlled.
Cite this article:
Harshal D. Patil, Chandrabhan B Patil, Vikas V. Patil, Pankaj S. Patil. An Overview on Quality by Design. Asian Journal of Research in Pharmaceutical Sciences. 2023; 13(1):49-5. doi: 10.52711/2231-5659.2023.00009
Cite(Electronic):
Harshal D. Patil, Chandrabhan B Patil, Vikas V. Patil, Pankaj S. Patil. An Overview on Quality by Design. Asian Journal of Research in Pharmaceutical Sciences. 2023; 13(1):49-5. doi: 10.52711/2231-5659.2023.00009 Available on: https://ajpsonline.com/AbstractView.aspx?PID=2023-13-1-9
REFERENCE:
1. Bhadra RM, Luhar S V, Narkhede SB, Professor A. A brief review on Quality by Design [QbD] a Systematic Approach Future pharmaceutical quality system: Paper Title:-A brief review on Quality by Design [QbD] a Systematic Approach. 2019; 6(6). Available from: www.jidps.com
2. Jayashri J.Bhise Omprakash G. Bhushnre. Journal of drug delivery and therapeutics (jddt). J Drug Deliv Ther. 2019; 9(3):661–8.
3. Q9: Quality Risk Management. ICH Harmonized Tripartite Guidelines. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. 2006.
4. Q10: Pharmaceutical Quality System, ICH Tripartite Guidelines. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. 2007.
5. Yu LX, Amidon G, Khan MA, Hoag SW, Polli J, Raju GK, et al. Understanding pharmaceutical quality by design. AAPS J. 2014; 16(4):771–83.
6. Gangaraj T, Nk S. A review on quality by design (QbD) - Its significance and applications. 2022; 15(1):2022.
7. Kumar VP, Vishal Gupta N. A review on quality by design approach (QBD) for pharmaceuticals. Int J Drug Dev Res. 2015; 7(1):52–60.
8. Supriya khatal. A review on quality by design. Vol. 5, International Journal of Pharmaceutical Chemistry and Analysis. 2020. p. 1–6.
9. Nadpara Nishendu P., Thumar Rakshit V. KVN. Aegeline from Aegle marmelos stimulates glucose transport via Akt and Rac1 signaling, and contributes to a cytoskeletal rearrangement through PI3K/Rac1. Int J Pharm Sci Rev Res. 2012;
10. Mohurle MSM, J. Asnani MDA, R. Chaple DD, Kurian MJ, G. Bais MA. Quality by Design (QbD): An Emerging Trend in Improving Quality and Development of Pharmaceuticals. Saudi J Med Pharm Sci. 2019; 05(12):1132–8.
11. Kumar Deepak, Ancheria Rahul, Soni Shankar lal SV. Asian Journal of Pharmaceutical Research and Development. Asian J Pharm Res Dev. 2019; 78–82.
12. Darkunde SL. A review on quality by design. Int J Pharm Chem Anal. 2020; 5(1):1–6.
13. Gage GP, Rudrapal M, Jadhav AG, Borser LB, Bendale AR. Review On Quality By Design (QbD). Asian J Pharm Educ Res. 2020; 9(2):37.
14. Sharma N, Singh S, Behl T, Gupta N, Gulia R, Kanojia N. Explicating the applications of quality by design tools in optimization of microparticles and nanotechnology based drug delivery systems. Biointerface Res Appl Chem. 2022; 12(4):4317–36.
15. Dahmash EZ, Al-Khattawi A, Iyire A, Al-Yami H, Dennison TJ, Mohammed AR. Quality by Design (QbD) based process optimisation to develop functionalised particles with modified release properties using novel dry particle coating technique. PLoS One. 2018; 13(11):1–20.
16. T. Anusha S and JVCS, Joginpally. Quality By Design: Its Applications. World J Pharm Life Sci. 2020; 6(1):180–6.
17. Mogal Vrushali, Dusane Jaydeep, Borse Pankaj PT. A Review on: Quality by Design (QbD). Pharm Biol Evalution. 2016; 3(3):313–9.
18. Harshraj R. Quality By Design Approach (QbD) For Pharmaceuticals : A Review. 2019; 6(6):853–61.
19. Patil A. S. and Pethe A. M., Quality by Design: A new concept for development of quality pharmaceuticals, Int. J. Pharm. Quality Assurance, 2013, (4) 13-19.
20. Mhatre R, Rathore AS. Quality by Design: An Overview of the Basic Concepts. Qual by Des Biopharm Princ Case Stud. 2008;
21. Yu LX. Pharmaceutical quality by design: Product and process development, understanding, and control. Pharm Res. 2008; 25(4):781–91.
22. Pramod K, Tahir Ma, Charoo N, Ansari S, Ali J. Pharmaceutical product development: A quality by design approach. Int J Pharm Investig. 2016; 6(3):129.
23. Bajare Niket D., Rewale Pravin, Chindrewar Shubham SA. Quality by Design. Int J Creat Reaserch Thoughts. 2020; 8(3):2757–66.
24. Chavan SD, Pimpodkar N V, Kadam AS, Gaikwad PS, Pharm PD. Research and Reviews : Journal of Pharmaceutical Quality Assurance Quality by Design. J Pharm Qual Assur. 2015; 1(2):18–24.
25. Suresh S, Roy S, Ahuja BK. Quality by design: An overview. Indian Drugs. 2015; 52(2):5–11.
26. Glodek M., Liebowitz S., McCarthy R., Mcnally G. and Schultz T, Process robustness – a PQRI white paper, Pharm. Eng, 2006 - 26 (6): 1-11. 18.
27. Kalyan S, Vihar P. Quality by Design : Changing Outlook of Pharmaceutical Development. Int J Pharm Sci Res. 2019; 10(9):4100–8.
28. Patel H, Parmar S, Patel B. A comprehensive review on quality by design (QbD) in pharmaceuticals. Int J Pharm Sci Rev Res. 2013; 21(1):223–36.
29. Sangshetti JN, Deshpande M, Zaheer Z, Shinde DB, Arote R. Quality by design approach: Regulatory need. Arab J Chem. 2017; 10(May):S3412–25.
30. International Council for Harmonisation. ICH guideline Q10 on pharmaceutical quality system. Eur Med Agency [Internet]. 2015; 44(September):1–20. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002871.pdf
31. ICH Quality implementation working group points to consider (R2) ICH-Endorsed Guide for ICHQ8/Q9/Q10 Implementation. Quality. 2011; 41(December):20.
32. Elliott P, Billingham S, Bi J, Zhang H. Quality by design for biopharmaceuticals: a historical review and guide for implementation. Pharm Bioprocess. 2013; 1(1):105–22.
33. U.S. Department of Health and Human Services Food and Drug Administration. ICH Q8(R2) Pharmaceutical Development. Work Qual by Des Pharm. 2009; 8(November):28.
34. Rajendra Phadke, Gosar A, Mali R, Patil D. a Review on Quality By Design Approaches To Analytical Method Development. Indo Am J Pharm Res. 2019; 9(7):3044–55.